Hong Kong stocks surged | Innovative drugs continue recent gains, foreign capital intensively acquiring shares of Chinese innovative drug companies, institutions optimistic about the return of core asset value in the second half of the year.

According to the Smart Finance and Economics APP, innovative drugs continue to rise in the near term. As of the time of writing, Sihuan Pharmaceutical (00460.HK) rose by 8% to 1.62 Hong Kong dollars; Hansoh Pharmaceutical Group-B (02142.HK) rose by 7.26% to 15.8 Hong Kong dollars; Jiangsu Hengrui Medicine (01276.HK) rose by 6.46% to 85.7 Hong Kong dollars; Mayo Clinic (02268) rose by 5.46% to 64.65 Hong Kong dollars; Federal Pharmaceutical (03933) rose by 5.23% to 17.3 Hong Kong dollars; and Jiangsu Chia Tai-Tech (01093) rose by 3.91% to 11.17 Hong Kong dollars.